Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,052
archived clinical trials in
Nephrology

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Metrolina Nephrology Associates, PA
349
mi
from 43215
Charlotte, NC
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Metrolina Nephrology Associates, PA
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Akron Nephrology Associates
110
mi
from 43215
Akron, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Akron Nephrology Associates
110
mi
from 43215
Akron, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Unversity of Oklahoma Health Sciences Center
847
mi
from 43215
Oklahoma City, OK
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Unversity of Oklahoma Health Sciences Center
847
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Northeast Clinical Research Center, LLC
407
mi
from 43215
Bethlehem, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Northeast Clinical Research Center, LLC
407
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Univ of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Temple University School of Medicine
416
mi
from 43215
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Temple University School of Medicine
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Le Bonheur Children's Hospital
508
mi
from 43215
Memphis, TN
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Le Bonheur Children's Hospital
508
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Clinical Advancement Center, PLLC
1136
mi
from 43215
San Antonio, TX
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Clinical Advancement Center, PLLC
1136
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Utah Kidney Research Center
1514
mi
from 43215
Salt Lake City, UT
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Utah Kidney Research Center
1514
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Univ of Washington
2006
mi
from 43215
Seattle, WA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Univ of Washington
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Catholic Health Initiatives Franciscan
2013
mi
from 43215
Tacoma, WA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Catholic Health Initiatives Franciscan
2013
mi
from 43215
Tacoma, WA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Marshfield Clinic Research Foundation
488
mi
from 43215
Marshfield, WI
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Marshfield Clinic Research Foundation
488
mi
from 43215
Marshfield, WI
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
UZ Leuven
4063
mi
from 43215
Leuven,
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
UZ Leuven
4063
mi
from 43215
Leuven,
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Southern Utah Kidney and Hypertension Center
1655
mi
from 43215
Saint George, UT
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Southern Utah Kidney and Hypertension Center
1655
mi
from 43215
Saint George, UT
Click here to add this to my saved trials
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Status: Enrolling
Updated:  3/21/2018
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Status: Enrolling
Updated: 3/21/2018
Univ of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
2039
mi
from 43215
Sacramento, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
2039
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
2102
mi
from 43215
Stanford, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
2102
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
667
mi
from 43215
Jacksonville, FL
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
667
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
432
mi
from 43215
Atlanta, GA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
563
mi
from 43215
Rochester, MN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
563
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
1936
mi
from 43215
Reno, NV
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
1936
mi
from 43215
Reno, NV
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
481
mi
from 43215
New York, NY
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
353
mi
from 43215
Chapel Hill, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
349
mi
from 43215
Durham, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
349
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
404
mi
from 43215
Bethlehem, PA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
404
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
524
mi
from 43215
Charleston, SC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
362
mi
from 43215
Chattanooga, TN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
995
mi
from 43215
Houston, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
1130
mi
from 43215
Lubbock, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
1130
mi
from 43215
Lubbock, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
316
mi
from 43215
Toronto,
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
316
mi
from 43215
Toronto,
Click here to add this to my saved trials
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated:  4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated: 4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated:  4/4/2018
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated: 4/4/2018
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Status: Enrolling
Updated:  4/4/2018
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Status: Enrolling
Updated: 4/4/2018
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Status: Enrolling
Updated:  4/9/2018
Children's Hospital of Pittsburgh of UPMC
165
mi
from 43215
Pittsburgh, PA
Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Status: Enrolling
Updated: 4/9/2018
Children's Hospital of Pittsburgh of UPMC
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Status: Enrolling
Updated:  4/19/2018
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Status: Enrolling
Updated: 4/19/2018
Montefiore Medical Center
484
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
282
mi
from 43215
Evanston, IL
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
282
mi
from 43215
Evanston, IL
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
453
mi
from 43215
New Brunswick, NJ
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
450
mi
from 43215
Somers Point, NJ
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
450
mi
from 43215
Somers Point, NJ
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
481
mi
from 43215
New York, NY
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
354
mi
from 43215
Durham, NC
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials